Mylan
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Mylan sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Mylan: 22 sponsored US clinical trials, none currently recruiting.
Mylan sponsors 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 21 completed. 13 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Obstructive Pulmonary Disease (COPD), with 2 trials.
Top-decile sponsor footprint
Mylan ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
21 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
22 total, page 1 of 1
Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain
NCT04571515
Mylan Insulin Aspart Study
NCT03760068
Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
NCT03502070
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
NCT03573817
Mylan Insulin Glargine Study
NCT03376789
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
NCT03095456
Thorough QT (TQT) Study of TD-4208 in Healthy Subjects
NCT02820311
Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis
NCT03107611
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
NCT02666430
Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment
NCT02578082
Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
NCT02581592
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
NCT02518139
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
NCT02512510
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
NCT02459080
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
NCT02772159
Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
NCT02449031
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
NCT02227875
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
NCT02227862
A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
NCT02040792
A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
NCT02109172
A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies
NCT02094716
Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
NCT00634166
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
| Phase 3 | 11 |
| Phase 4 | 2 |
Therapeutic Areas
How the Mylan archive is shaped
22 indexed studies, none listed as recruiting (0% open); 21 completed (95%).
Phase mix: 13 late (III/IV) vs 8 early (I/II) (later-stage heavy).
Top condition: Chronic Obstructive Pulmonary Disease (COPD) (2 trials), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Mylan: archived-pipeline peers nationwide
Peers matched on 22 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Mylan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 archived trials
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Mylan page
22 registered trials is a research-attention snapshot, not an endorsement of Mylan or any single study.
- None of Mylan's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Chronic Obstructive Pulmonary Disease (COPD) is the condition Mylan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Obstructive Pulmonary Disease (COPD) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mylan pipeline card: 22 registered trials from official public datasets.Report a data error.